SAN FRANCISCO--(BUSINESS WIRE)--
RDMD, a healthcare technology company dedicated to accelerating research for patients with rare diseases, today announced key leadership members will be participating in the following upcoming industry events this fall:
● Technology & Rare Neurological Diseases Symposium (TRNDS), being held Friday, September 13 in Rochester, NY. RDMD co-founder and chief executive officer Nancy Yu will participate in the panel “Real World Evidence” at 2:45 p.m. ET;
● Global Genes’ Rare Patient Advocacy Summit, being held September 18-20 in San Diego, Calif. RDMD co-founder Onno Faber will speak with other rare disease patient leaders at the panel “Challenge Your Limits,” moderated by the hosts of the podcast “The Two Disabled Dudes” at 4:15 p.m. PST on Thursday, September 19;
● TEDx San Francisco on Thursday, October 3 in San Francisco. RDMD co-founder Onno Faber will give a talk about his journey as a citizen scientist and patient advocate; and,
● Duke Margolis Center for Health Policy’s 3rd Annual Conference on Real-world Data and Evidence, titled, “Developing Real-World Data and Evidence to Support Regulatory Decision-Making” at the National Press Club in Washington, D.C. on Thursday, October 3. Co-founder and chief executive officer Nancy Yu will participate in the panel “Establishing a High-Quality Real-World Data Ecosystem” at 9:30 a.m. ET.
RDMD is a healthcare technology company dedicated to accelerating drug development for patients with rare diseases. RDMD has developed a technology platform that generates deep data insights to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to get access to and benefit from their own medical data. RDMD was co-founded by Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2, and Nancy Yu, former head of corporate development at 23andMe. The company is backed by Lux Capital, Village Global, First Round's Healthcare Co-Op and a number of angel investors. For more information, visit www.rdmd.com.